


COMMUNICATIONS

Redox chemotherapy: Antiproliferative activities of a series of N-substituted 1,2-dihydroquinolines capable of causing redox imbalance in cancer cells are presented. Detailed studies showed that these derivatives arrest the cell cycle in the G₂/M phase and induce apoptosis through an intrinsic pathway characterized by loss of mitochondrial membrane potential, DNA fragmentation, cytochrome c release, and activation of caspases 9 and 3.



N. John Victor, R. Sakthivel,
K. M. Muraleedharan,* D. Karunakaran*



**N-Substituted 1,2-Dihydroquinolines
as Anticancer Agents: Electronic
Control of Redox Stability, Assessment
of Antiproliferative Effects, and
Mechanistic Insights**



DOI: 10.1002/cmdc.201300210

N-Substituted 1,2-Dihydroquinolines as Anticancer Agents: Electronic Control of Redox Stability, Assessment of Antiproliferative Effects, and Mechanistic Insights


Napoleon John Victor,^[a] Ramasamy Sakthivel,^[b] Kannoth Manheri Muraleedharan,^{*,[a]} and Devarajan Karunakaran^{*,[b]}

Quinolines and quinolones are privileged core structures in various therapeutic agents, especially those used against infectious diseases. Antimalarial drugs such as chloroquine, mefloquine, and primaquine,^[1] and antibacterial agents such as ciprofloxacin, levofloxacin, and norfloxacin,^[2] are some of the well-known examples from these groups. Our laboratory recently reported the synthesis of 4- and 2-quinolones from Baylis–Hillman acetates and amines through an $S_N2' \rightarrow S_NAr \rightarrow (\Delta^{3,4} - \Delta^{2,3} \text{ shift}) \rightarrow$ oxidation sequence involving 1,2-dihydroquinolines (DHQs) as key intermediates.^[3] Subsequent analyses showed that these DHQs, though sensitive to light and oxygen, can gain stability if the aromatic ring is substituted with electron-withdrawing groups. Because compounds such as menadione, ascorbic acid, and piperlongumine can elicit an antiproliferative response by directly or indirectly perturbing the redox balance in rapidly proliferating cells, we envisaged that DHQs will also be interesting candidates for further study.^[4] Results from our investigations in this direction are presented here.

A literature search revealed that DHQs have not received significant attention in drug design, likely due to their decreased stability. Synthetic DHQ derivatives with 1,2- or 2,2-disubstitution pattern have been shown to act as anti-inflammatory agents (e.g., compound I)^[5] or HIV-1 reverse transcriptase inhibitors (e.g., compound II).^[6] In addition, derivatives of 2,2,4-trisubstituted DHQs are well known as lipid peroxidation inhibitors,^[7] glucocorticoid receptor modulators (e.g., compound III),^[8] and antioxidants.^[9] Interestingly, esters of 2,2,4-trimethyl-1,2-dihydroquinoline-6-ols (e.g., compound IV) were found to be redox-active due to the possibility of quinone imine formation through electron transfer after deacetylation by trypanosomal esterases.^[10] A number of DHQ derivatives from this group possess antitrypanosomal activity with IC_{50} values in the nanomolar range. Their ability to exert strain on the antioxi-

dant machinery of the parasite by generating reactive oxygen species (ROS) is believed to be responsible for the activity.

Replacement of the C2 and C4 hydrogen atoms by alkyl groups (as in compound III) or acylation of the ring nitrogen



(as in compound II) is likely to lower the propensity of the compound to undergo oxidative transformations. The tendency of 1,4-DHQs to undergo redox transformation in biological milieu was made use of by Foucort and co-workers in the development of a chemical delivery system (CDS) for central nervous system (CNS)-active agents, such as γ -aminobutyric acid (GABA) and *meta*-iodobenzylguanidine (V).^[11] These compounds, when conjugated to 1,4-DHQ, were able to cross the blood brain barrier with ease, and the formation of quinolinium salt inside the cells led to accumulation of the agent through an ion trap mechanism. Because cancer cells are more susceptible than normal cells to redox imbalance, DHQs are attractive candidates for selectively targeting malignant cells.^[4]

Synthesis of 1,2-DHQ derivatives 5–7 typically involves formation of the Baylis–Hillman adduct from the appropriate aromatic aldehyde and α,β -unsaturated carbonyl compound,^[12] its acetylation to form intermediate 3, and subsequent tandem $S_N2' \rightarrow S_NAr$ reactions using an amine of interest.^[3,13] The required 1,2-DHQs were obtained in moderate to good yields (Scheme 1).


DHQs 5–7 differ in the nature of the substituent on the aromatic ring. In order to get an understanding of their cytotoxic effects, the viability of HeLa, SiHa and SW480 cell lines after incubation with these compounds was studied by MTT assay, and the results are presented in Table 1. Among these, the 6,7-difluoro- and 6-nitro-substituted DHQs (5 and 7.1, respectively) were more potent than the 5,6,7,8-tetrafluoro-substituted de-

[a] N. John Victor,⁺ Dr. K. M. Muraleedharan
Department of Chemistry
Indian Institute of Technology Madras, Chennai, 600036 (India)
E-mail: mkm@iitm.ac.in

[b] R. Sakthivel,⁺ Prof. D. Karunakaran
Department of Biotechnology
Indian Institute of Technology Madras, Chennai, 600036 (India)
E-mail: karuna@iitm.ac.in

[⁺] These authors contributed equally to this work.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/cmdc.201300210>.



Scheme 1. Synthesis of dihydroquinolines **5**, **6**, and **7.1–7.10**. *Reagents and conditions:* a) 1,4-diazabicyclo[2.2.2]octane (DABCO), THF, 27 °C, 24–48 h; b) AcCl, Et₃N, CH₂Cl₂, 0 °C → RT, 1–2 h; c) R⁵NH₂ (**4**), NMP (*N*-methyl pyrrolidone), K₂CO₃, 27 °C, 1–12 h. Full protocol details and characterization data are given in the Experimental Section and Supporting Information.


relative **6**. Considering the inhibitory effects and the ease of synthesis of compound **7.1**, a subset of compounds (**7.2–7.10**) was then prepared by varying the nature of the *N*-substitution and subjected to cytotoxicity evaluation. Interestingly, all of these compounds showed antiproliferative effects in a concentration-dependent manner and had IC₅₀ values in the range of 5.2–84 μM (Table 1). 1-Phenylethylamine- and serine-based

Table 1. Cytotoxic effects of 1,2-dihydroquinoline (DHQ) derivatives against three human cancer cell lines.^[a]

Compd	IC ₅₀ [μM]		
	HeLa	SiHa	SW480
5	47.8 ± 1.0	32.4 ± 6.1	33.2 ± 0.4
6	> 100	> 100	> 100
7.1	42.4 ± 4.0	47.3 ± 1.4	37.3 ± 2.0
7.2	20.3 ± 0.5	24.1 ± 4.6	18.8 ± 0.7
7.3	19.6 ± 1.5	18.0 ± 0.3	12.6 ± 0.4
7.4	29.7 ± 0.8	27.1 ± 1.0	20.4 ± 0.7
7.5	27.4 ± 1.0	23.0 ± 0.3	20.5 ± 0.6
7.6	34.4 ± 2.9	27.3 ± 2.1	19.0 ± 1.0
7.7	17.6 ± 3.5	5.2 ± 0.9	5.7 ± 0.3
7.8	13.9 ± 0.3	7.5 ± 0.2	9.0 ± 0.3
7.9	84.0 ± 2.1	72.5 ± 3.5	60 ± 0.8
7.10	8.5 ± 0.3	6.8 ± 1.8	5.2 ± 0.1

[a] Cells were treated with various concentrations of test compound and incubated for 72 h; DMSO was used as the vehicle-only control; cell viability was determined by MTT assay, and the IC₅₀ values were calculated from the results. Data represent the mean ± SD of three independent experiments performed in triplicate.

DHQs **7.7**, **7.8** and **7.10** were superior in terms of their inhibitory activities. As the oxidation of these DHQs after cellular uptake is a possibility, we prepared quinolones **8–12**, quinoline **13** and quinolinium salts **14–15** to investigate whether such activation in vivo is responsible for the observed cytotoxicity.^[3]



When assayed against HeLa cells, the IC₅₀ values of these compounds were found to be greater than 100 μM suggesting that the biological effects from such species, if at all, would be rather weak; this does not undermine the effect from redox reactions involving DHQs in which quinolinium ions could be a byproduct.

There are a number of anticancer agents that exert their effect by inducing apoptosis, a process characterized by plasma membrane blebbing, externalization of phosphatidylserine, cell shrinkage, nuclear and cytoplasmic condensation, cytochrome c release, activation of caspases, and DNA fragmentation.^[14] In order to assess the cellular effects of exposure to DHQs, the most active compounds (**7.10** and **7.7**) were subjected to further analysis. Because cleavage of DNA into oligonucleosomal-sized fragments is an indication of apoptosis, these compounds were first evaluated in a DNA fragmentation assay according to the reported protocol.^[15] Western blot analysis of lysates from HeLa cells treated with these DHQs clearly showed DNA laddering, which point toward their ability to induce apoptosis (Figure 1).

Apoptosis is accompanied by a loss of mitochondrial membrane potential that can be studied using JC-1, a cationic dye capable of undergoing a reversible change in fluorescence emission.^[16] High membrane potential promotes aggregation of the dye inside the mitochondria, where it fluoresces orange. At the same time, cells with low potential contain monomeric JC-1 in the cytoplasm, where it fluoresces green. During our studies, the dye was found localized in the mitochondria of DMSO-treated (control) HeLa cells (Figure 2a), where it formed orange fluorescent aggregates. However, there was a notable




Figure 1. DNA fragmentation induced in HeLa cells by DMSO (control), Taxol (25 nM), 7.7 (25 μ M) and 7.10 (25 μ M).

loss of mitochondrial membrane potential after 24 h treatment of the cells with Taxol and 7.10, as indicated by green fluorescence (Figure 2 b,c respectively).

Caspases are a family of cytosolic cysteine proteases involved in the initiation and execution of apoptosis.^[17] In mitochondrion-dependent apoptosis, cytochrome c is released into the cytosol where it binds with Apaf1 and procaspase-9 form-




Figure 2. Fluorescence microscopic images of HeLa cells stained with JC-1 after 24 h exposure to a) DMSO, b) Taxol (12 nM), and c) 7.10 (25 μ M).

ing an apoptosome complex, which then gives caspase-9; subsequent activation of downstream effectors such as caspase-3 triggers apoptosis.^[18] In order to see whether DHQs operate through a mitochondrion-mediated mechanism, HeLa cells were incubated with 7.7 (25 μ M) or 7.10 (25 μ M) for 48 h and analyzed for cytochrome c, cleaved caspase-9, and cleaved caspase-3 expression by Western blot. Results indicate that these compounds trigger release of cytochrome c, and cleaved caspases 9 and 3, which confirmed that these DHQs induce apoptosis via a mitochondrial pathway (Figure 3).

Subsequently, flow cytometry was performed to evaluate the effect of DHQs on the cell cycle.^[19] HeLa cells were treated with 7.10 (12.5 μ M) for 24 h, fixed, stained by propidium iodide (PI) and analyzed using DMSO and Taxol (12 nM) as negative and positive controls, respectively (Figure 4). Compound 7.10 caused depletion of cells in the G₀/G₁ phase with a concomitant accumulation of cells in the G₂/M phase indicating a G₂/M arrest (Figure 4 a). An increase was also observed in the apoptotic fraction; the S phase, however, seemed unaffected relative to the DMSO-treated control cells. Treatment of cells for 24 h with 7.10 resulted in 26% apoptotic cells whereas




Figure 3. Western blots obtained after exposing HeLa cells to Taxol (12 nM), 7.7 (25 μ M), and 7.10 (25 μ M). The following effects were observed: a) cytochrome c release into cytosol, b) activation of cleaved caspase-9, and c) activation of cleaved caspase-3.

only 8.8% apoptotic cells were seen in vehicle-only control cells (Figure 4 b). Similarly, there were 26.8% of G₂/M-phase cells compared with 13.1% in vehicle-only control cells (Figure 4 c). These data were determined to be statistically significant ($p < 0.01$) suggesting that 7.10 and related compounds induce G₂/M phase cell-cycle arrest.

To investigate the possibility of DHQ-induced apoptosis through the formation of ROS, a cell-based assay using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) was carried out.^[20] Intracellular ROS were detected using the redox-sensitive fluorescent dye DCFH-DA, a membrane permeable fluorogenic reagent that measures the

ROS activity within a cell. After diffusion into the cell, DCFH-DA is deacetylated by cellular esterases to a non-fluorescent compound, which undergoes oxidation by ROS to the highly fluorescent derivative 2',7'-dichlorofluorescein (DCF). The production of ROS was determined by measuring the intensity of the fluorescence (Figure 5 a). Relative DCF fluorescence intensities were quantitated from the representative images of cells treated with 7.7 (42.23 ± 0.004) and 7.10 (32.45 ± 0.78) and compared with the control group (6.069 ± 0.03) (Figure 5 b). A significant increase in intracellular ROS was observed in cells subjected to oxidative stress injury caused by DHQs 7.7 and 7.10 but not in the control cells. To determine whether intracellular ROS increment originates directly from the compound or indirectly after its effect on mitochondria, the DCFH-DA assay was carried out with varying incubation times (i.e., 15 min, 30 min, 1 h, 6 h, and 12 h). The results indicate that oxidative stress induced by DHQs is very rapid, and hence the generated ROS is likely due to a direct effect (for details, see the Supporting Information).

Although cancer cells depend on ROS-based signaling for hyperproliferation, they are very sensitive to fluctuations in




Figure 4. Flow cytometric analysis of HeLa cells. a) Cell-cycle histograms of HeLa cells treated with DMSO, Taxol (12 nM), and 7.10 (12.5 μM). Statistical analysis of b) percentage of apoptotic cells, and c) percentage of G₂/M phase cells. Data represent the mean ± SEM of three independent experiments performed in triplicate.




Figure 5. Dihydroquinolines (DHQs) induce ROS accumulation in HeLa Cells. a) Representative fluorescent photomicrographs showing relative (rel.) 2',7'-dichlorofluorescein (DCF) fluorescence in cells treated with DMSO (control), 7.7 (25 μM), 7.10 (25 μM), and *tert*-butyl hydroperoxide (*t*-BHP) (100 μM). b) Quantification of reactive oxygen species (ROS) production as determined by DCF fluorescence. b) Bar graphs presenting the ROS accumulation data. Values represent the mean ± SEM of *n* = 2 independent experiments performed in triplicate; *** *p* < 0.001 vs. control.

redox status. For this reason, compounds capable of inducing redox imbalance can potentially target such cells. While reactivity and interaction with multiple targets might be considered a drawback for drug development, if good selectivity can be achieved, these same features could help overcome resist-

ance, which is a major concern for many anticancer drugs in clinical use. Active interest in the area of redox chemotherapy is evident from drug candidates such as 2-methoxyestradiol (phase II), disulfiram (phase II), motexafin gadolinium (phase III), and β-lapachone (phase II), which have all reached advanced

stages of clinical development.^[4a,21] The results presented here clearly show that 1,2-DHQs induce oxidative stress in HeLa cells. As normal cells are known to be less susceptible to small fluctuations in ROS levels due to the presence of antioxidant defense mechanisms, the compounds discussed here can be considered as leads for the development of new drug candidates. The ready availability of starting materials, ease of synthesis, and possibility of structural diversification for structure–activity relationship studies are all advantages of this class of compounds. Efforts to discover highly potent compounds in this class, preferably with IC₅₀ values in the low nanomolar range, and investigations to identify the specific targets, if any, of these compounds are currently underway.

In conclusion, we have discovered a novel series of 1,2-dihydroquinoline (DHQ) derivatives with promising anticancer activities. Detailed biochemical studies showed that they are capable of inducing apoptosis as evidenced by DNA fragmentation, disruption of mitochondrial membrane potential, cytochrome c release, and activation of caspase-9 and caspase-3. Their ability to induce oxidative stress in cancer cells was unequivocally confirmed by DCFH-DA fluorescence assay. Flow cytometric analysis of HeLa cells treated with a representative compound (**7.10**) revealed that these DHQs cause cell-cycle arrest in the G₂/M phase. Taken together, these observations point toward the operation of an intrinsic pathway of apoptosis in the presence of these compounds. Detailed structure–activity relationship studies and efforts to gain an understanding of their biological effects at a molecular level are currently in progress.

Experimental Section

General procedure for the preparation of dihydroquinolines: A stirred solution of the Baylis–Hillman acetate (1 equiv) in *N*-methyl pyrrolidone (6 mL mmol⁻¹) under a nitrogen atmosphere was treated with K₂CO₃ (1.5 equiv). The appropriate amine (2 equiv) was then added to the reaction mixture, and stirring was continued at room temperature for 1–12 h. After completion (determined by TLC), water was added until the solution became turbid, and the mixture was stirred for an additional 30 min. The precipitated product was isolated by filtration, washed with water and dried in vacuo. This near-pure material was then purified further to remove trace impurities by column chromatography (EtOAc/hexanes; gradient elution). Isolated yields of dihydroquinolines ranged from 50–85%. Spectral data of representative examples (**7.7** and **7.10**) are given below, and that of other compounds are given in the Supporting Information.

(R)-Methyl 6-nitro-1-(1-phenylethyl)-1,2-dihydroquinoline-3-carboxylate (7.7): Reaction of the appropriate Baylis–Hillman acetate **3** (R¹=R³=R⁴=H, R²=NO₂, X=Cl) (200 mg, 0.64 mmol) for 5 h according to the procedure described above yielded **7.7** as a yellow gummy solid (162 mg, 75%); R_f=0.43 (EtOAc/hexanes, 1:4); ¹H NMR (400 MHz, CDCl₃): δ=8.00 (dd, J=9.2, 2.4 Hz, 1H, ArH), 7.90 (d, J=2.8 Hz, 1H, ArH), 7.41–7.29 (m, 6H, ArH, -C₄H), 6.64 (d, J=9.2 Hz, 1H, ArH), 5.20 (q, J=6.8 Hz, 1H, N-CH), 4.35 (d, J=16.0 Hz, 1H, N-CH₃H_b), 4.14 (d, J=16.0 Hz, 1H, N-CH₃H_b), 3.76 (s, 3H, OCH₃), 1.69 ppm (d, J=6.8 Hz, 3H, CH₃-CH); ¹³C NMR (100 MHz, CDCl₃): δ=165.2, 151.2, 139.0, 137.6, 134.1, 129.1 (2C), 128.4, 128.1, 127.0 (2C), 126.0, 122.8, 119.6, 110.0, 55.8, 52.1, 43.3,

15.5 ppm; IR (neat): ν̄=1708, 1601, 1574, 1499, 1436, 1324, 1289, 1233, 1165, 1106 cm⁻¹; HRMS-ESI: m/z [M+K]⁺ calcd for C₁₉H₁₈N₂O₄K: 377.0904, found: 377.0897.

(S)-Methyl 1-(3-hydroxy-1-methoxy-1-oxopropan-2-yl)-6-nitro-1,2-dihydroquinoline-3-carboxylate (7.10): Reaction of the appropriate Baylis–Hillman acetate **3** (R¹=R³=R⁴=H, R²=NO₂, X=Cl) (200 mg, 0.64 mmol) for 12 h according to the procedure described above yielded **7.10** as a yellow solid (176 mg, 82%); R_f=0.26 (EtOAc/hexanes, 1:1); mp: 134–137 °C; ¹H NMR (400 MHz, CDCl₃): δ=8.02 (dd, J=9.2, 2.8 Hz, 1H, ArH), 7.92 (d, J=2.4 Hz, 1H, ArH), 7.35 (s, 1H, -C₄H), 6.52 (d, J=9.2 Hz, 1H, ArH), 4.55–4.48 (m, 2H, N-CH₃H_b/N-CH), 4.34 (d, J=15.2 Hz, 1H, N-CH₃H_b), 4.25 (dd, J=11.6, 5.6 Hz, 1H, CH₃H_bOH), 4.09 (dd, J=11.6, 7.2 Hz, 1H, CH₃H_bOH), 3.83 (s, 3H, -OCH₃), 3.81 (s, 3H, -OCH₃), 2.22 ppm (brs, 1H, -OH); ¹³C NMR (100 MHz, CDCl₃): δ=169.9, 165.1, 151.0, 139.0, 133.8, 127.9, 125.8, 123.5, 120.7, 110.3, 62.6, 59.8, 53.0, 52.3, 45.6 ppm; IR (KBr): ν̄=3457, 2954, 1740, 1721, 1640, 1573, 1495, 1434, 1324, 1298, 1221, 1174, 1088, 1010, 929, 817, 742 cm⁻¹; HRMS-ESI: m/z [M+Na]⁺ calcd for C₁₅H₁₆N₂O₇Na: 359.0855, found 359.0866.

Acknowledgements

Financial support of this work by the Council of Scientific & Industrial Research (CSIR), India (01(2121)/07/EMR-II) and the Indian Ministry of Science and Technology through the Department of Science and Technology (DST) (SR/S1/OC-13/2007) and the Department of Biotechnology (DBT) (BT/01/COE/07/04) is gratefully acknowledged N.J.V. and R.S. thank the CSIR for research fellowships.

Keywords: apoptosis · cytotoxic agents · dihydroquinolines · G₂/M cell-cycle arrest · reactive oxygen species

- [1] M. Foley, L. Tilley, *Pharmacol. Ther.* **1998**, *79*, 55–87.
- [2] L. A. Mitscher, *Chem. Rev.* **2005**, *105*, 559–592.
- [3] J. V. Napoleon, M. K. Manheri, *Synthesis* **2011**, 3379–3388.
- [4] a) J. Verrax, R. Beck, N. Dejeans, C. Glorieux, B. Sid, R. C. Pedrosa, J. Benites, D. Vásquez, J. A. Valderrama, P. B. Calderon, *Anti-Cancer Agents Med. Chem.* **2011**, *11*, 213–221; b) L. Raj, T. Ide, A. U. Gurkar, M. Foley, M. Schenone, X. Li, N. J. Tolliday, T. R. Golub, S. A. Carr, A. F. Shamji, A. M. Stern, A. Mandinova, S. L. Schreiber, S. W. Lee, *Nature* **2011**, *475*, 231–234; c) D. N. Criddle, S. Gillies, H. K. Baumgartner-Wilson, M. Jaffar, E. C. Chinje, S. Passmore, M. Chvanov, S. Barrow, O. V. Gerasimenko, A. V. Tepikin, R. Sutton, O. H. Petersen, *J. Biol. Chem.* **2006**, *281*, 40485–40492.
- [5] R. D. Dillard, D. E. Pavey, D. N. Benslay, *J. Med. Chem.* **1973**, *16*, 251–253.
- [6] I. W. Althaus, A. J. Gonzales, J. J. Chou, D. L. Romero, M. R. Deibel, K.-C. Chou, F. J. Kezdy, L. Resnick, M. E. Busso, A. G. So, K. M. Downey, R. C. Thomas, P. A. Aristoff, W. G. Tarpley, F. Reusser, *J. Biol. Chem.* **1993**, *268*, 14875–14880.
- [7] a) A. Blazovics, A. Somogyi, G. Lengyel, I. Lang, J. Feheár, *Free Radical Res. Commun.* **1988**, *4*, 409–413; b) F. Dallacker, K. Reperich, M. Mayer, *Chem.-Ztg.* **1991**, *115*, 203–208.
- [8] a) H. Takahashi, Y. Bekkali, A. J. Capolino, T. Gilmore, S. E. Goldrick, P. V. Kaplita, L. Liu, R. M. Nelson, D. Terenzio, J. Wang, L. Zuvela-Jelaska, J. Proudfoot, G. Nabozny, D. Thomson, *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5091–5095; b) S. W. Elmore, M. J. Coghlan, D. D. Anderson, J. K. Pratt, B. E. Green, A. X. Wang, M. A. Stashko, C. W. Lin, C. M. Tyree, J. N. Miner, P. B. Jacobson, D. M. Wilcox, B. C. Lane, *J. Med. Chem.* **2001**, *44*, 4481–4491; c) M. J. Coghlan, P. R. Kym, S. W. Elmore, A. X. Wang, J. R. Luly, D. Wilcox, M. Stashko, C.-W. Lin, J. Miner, C. Tyree, M. Nakane, P. Jacobson, B. C. Lane, *J. Med. Chem.* **2001**, *44*, 2879–2885.
- [9] a) L. Prónai, A. Blazovics, M. Horvath, I. Lang, J. Fehér, *Free Radical Res. Commun.* **1993**, *19*, 287–296; b) B. C. Pearce, J. J. Wright, US 5411969A 19930416, **1995**.

- [10] J. Fotie, M. Kaiser, D. A. Delfin, J. Manley, C. S. Reid, J.-M. Paris, T. Wenzler, L. Maes, K. V. Mahasenan, C. Li, K. A. Werbovetz, *J. Med. Chem.* **2010**, *53*, 966–982.
- [11] a) F. Gourand, G. Mercey, M. Ibazizene, O. Tirel, J. Henry, V. Levacher, C. Perrio, L. Barre, *J. Med. Chem.* **2010**, *53*, 1281–1287; b) L. Foucout, F. Gourand, M. Dhilly, P. Bohn, G. Dupas, J. Costentin, A. Abbas, F. Marsais, L. Barre, V. Levacher, *Org. Biomol. Chem.* **2009**, *7*, 3666–3673.
- [12] A. B. Baylis, M. E. D. Hillman, German Patent 2155113, **1972**.
- [13] J. N. Kim, H. S. Kim, J. H. Gong, Y. M. Chung, *Tetrahedron Lett.* **2001**, *42*, 8341–8344.
- [14] A. Saraste, K. Pulkki, *Cardiovasc. Res.* **2000**, *45*, 528–537.
- [15] a) J. H. Zhang, M. Xu, *Cell Res.* **2000**, *10*, 205–211; b) D. Hockenbery, G. Nunez, C. Milliman, R. D. Schreiber, S. J. Korsmeyer, *Nature* **1990**, *348*, 334–336.
- [16] a) S. T. Smiley, M. Reers, C. Mottola-Hartshorn, M. Lin, A. Chen, T. W. Smith, G. D. Steele, Jr., L. B. Chen, *Proc. Natl. Acad. Sci. USA* **1991**, *88*, 3671–3675; b) B. G. Heerd, M. A. Houston, G. M. Anthony, L. H. Augenlicht, *Cancer Res.* **1998**, *58*, 2869–2875.
- [17] I. Budihardjo, H. Oliver, M. Lutter, X. Luo, X. Wang, *Annu. Rev. Cell Dev. Biol.* **1999**, *15*, 269–290.
- [18] a) D. Acehan, X. Jiang, D. G. Morgan, J. E. Heuser, X. Wang, C. W. Akey, *Mol. Cell* **2002**, *9*, 423–432; b) H.-E. Kim, F. Du, M. Fang, X. Wang, *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 17545–17550.
- [19] a) R. S. DiPaola, *Clin. Cancer Res.* **2002**, *8*, 3311–3314; b) C. Riccardi, I. Nicoletti, *Nat. Protoc.* **2006**, *1*, 1458–1461.
- [20] a) C. P. LeBel, H. Ischiropoulos, S. C. Bondy, *Chem. Res. Toxicol.* **1992**, *5*, 227–231; b) M. T. Hoyt, R. Palchadhuri, P. J. Hergenrother, *Invest. New Drugs* **2011**, *29*, 562–573.
- [21] G. T. Wondrak, *Antioxid. Redox Signaling* **2009**, *11*, 3013–3069.

Received: May 12, 2013

Revised: July 12, 2013

Published online on ■ ■ ■ ■, 0000